Conformational HIV-1 Envelope on particulate structures: a tool for chemokine coreceptor binding studies

The human immunodeficiency virus type 1 (HIV-1) external envelope glycoprotein gp120 presents conserved binding sites for binding to the primary virus receptor CD4 as well as the major HIV chemokine coreceptors, CCR5 and CXCR4.Concerted efforts are underway to understand the specific interactions between gp120 and coreceptors as well as their contribution to the subsequent membrane fusion process.The present review summarizes the current knowledge on this biological aspect, which represents one of the key and essential points of the HIV-host cell interplay and HIV life cycle. The relevance of conformational HIV-1 Envelope proteins presented on Virus-like Particles for appropriate assessment of this molecular interaction, is also discussed.

[1]  Xin Wang,et al.  TAK-652 Inhibits CCR5-Mediated Human Immunodeficiency Virus Type 1 Infection In Vitro and Has Favorable Pharmacokinetics in Humans , 2005, Antimicrobial Agents and Chemotherapy.

[2]  Zhaowen Luo,et al.  Structural and Functional Characterization of Human CXCR4 as a Chemokine Receptor and HIV-1 Co-receptor by Mutagenesis and Molecular Modeling Studies* , 2001, The Journal of Biological Chemistry.

[3]  S. Durell,et al.  Dilation of the Human Immunodeficiency Virus–1 Envelope Glycoprotein Fusion Pore Revealed by the Inhibitory Action of a Synthetic Peptide from gp41 , 1998, The Journal of cell biology.

[4]  D. Littman,et al.  Expression cloning of new receptors used by simian and human immunodeficiency viruses , 1997, Nature.

[5]  D. Cooper,et al.  A Phase I study to explore the activity and safety of SCH532706, a small molecule chemokine receptor-5 antagonist in HIV type-1-infected patients , 2009, Antiviral therapy.

[6]  Dominique Schols,et al.  Safety, Pharmacokinetics, and Antiviral Activity of AMD3100, a Selective CXCR4 Receptor Inhibitor, in HIV-1 Infection , 2004, Journal of acquired immune deficiency syndromes.

[7]  C. Broder,et al.  Differential utilization of CCR5 by macrophage and T cell tropic simian immunodeficiency virus strains. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[8]  R. Doms,et al.  Focused dampening of antibody response to the immunodominant variable loops by engineered soluble gp140. , 2008, AIDS research and human retroviruses.

[9]  A. Kingsman,et al.  Immunogenicity of the yeast recombinant p17/p24:Ty virus-like particles (p24-VLP) in healthy volunteers. , 1995, Vaccine.

[10]  P. Coursaget,et al.  In vitro gene transfer using human papillomavirus-like particles. , 1998, Nucleic acids research.

[11]  R. Bonavia,et al.  Stromal cell-derived factor-1alpha (SDF-1alpha/CXCL12) stimulates ovarian cancer cell growth through the EGF receptor transactivation. , 2005, Experimental cell research.

[12]  E. Cortés,et al.  Recombinant vaccine for canine parvovirus in dogs , 1992, Journal of virology.

[13]  R. Compans,et al.  Assembly of SIV virus-like particles containing envelope proteins using a baculovirus expression system. , 1995, Virology.

[14]  C. Broder,et al.  Substitutions in a Homologous Region of Extracellular Loop 2 of CXCR4 and CCR5 Alter Coreceptor Activities for HIV-1 Membrane Fusion and Virus Entry* , 2000, The Journal of Biological Chemistry.

[15]  B. Haynes,et al.  Incorporation of High Levels of Chimeric Human Immunodeficiency Virus Envelope Glycoproteins into Virus-Like Particles , 2007, Journal of Virology.

[16]  Eva Chung,et al.  HIV-1 gp120 induces NFAT nuclear translocation in resting CD4+ T-cells. , 2006, Virology.

[17]  J. Binley,et al.  Effect of trimerization motifs on quaternary structure, antigenicity, and immunogenicity of a noncleavable HIV-1 gp140 envelope glycoprotein. , 2009, Virology.

[18]  A. Trkola,et al.  Estimating the Stoichiometry of Human Immunodeficiency Virus Entry , 2008, Journal of Virology.

[19]  J. Sodroski,et al.  Conformational changes of gp120 in epitopes near the CCR5 binding site are induced by CD4 and a CD4 miniprotein mimetic. , 1999, Biochemistry.

[20]  E. Freed,et al.  Mutational analysis of the cleavage sequence of the human immunodeficiency virus type 1 envelope glycoprotein precursor gp160 , 1989, Journal of virology.

[21]  J. Ferbas,et al.  Enhanced Binding of Antibodies to Neutralization Epitopes following Thermal and Chemical Inactivation of Human Immunodeficiency Virus Type 1 , 2000, Journal of Virology.

[22]  Tongqing Zhou,et al.  Structural Basis for Broad and Potent Neutralization of HIV-1 by Antibody VRC01 , 2010, Science.

[23]  K. V. Van Rompay.  Evaluation of antiretrovirals in animal models of HIV infection. , 2010, Antiviral research.

[24]  Wayne C Koff,et al.  HIV vaccine design and the neutralizing antibody problem , 2004, Nature Immunology.

[25]  M. Oppermann.  Chemokine receptor CCR5: insights into structure, function, and regulation. , 2004, Cellular signalling.

[26]  P. Earl,et al.  Native oligomeric human immunodeficiency virus type 1 envelope glycoprotein elicits diverse monoclonal antibody reactivities , 1994, Journal of virology.

[27]  Gregory J Babcock,et al.  Ligand-independent Dimerization of CXCR4, a Principal HIV-1 Coreceptor* , 2003, The Journal of Biological Chemistry.

[28]  Deborah Fass,et al.  Core Structure of gp41 from the HIV Envelope Glycoprotein , 1997, Cell.

[29]  P. Sehgal,et al.  Characterization of infectious molecular clones of simian immunodeficiency virus (SIVmac) and human immunodeficiency virus type 2: persistent infection of rhesus monkeys with molecularly cloned SIVmac , 1988, Journal of virology.

[30]  Yuntao Wu,et al.  Chemokine Coreceptor Signaling in HIV-1 Infection and Pathogenesis , 2009, PLoS pathogens.

[31]  R. Doms,et al.  Two distinct CCR5 domains can mediate coreceptor usage by human immunodeficiency virus type 1 , 1997, Journal of virology.

[32]  Joseph Sodroski,et al.  Tyrosine Sulfation of the Amino Terminus of CCR5 Facilitates HIV-1 Entry , 1999, Cell.

[33]  William C. Olson,et al.  Amino-Terminal Substitutions in the CCR5 Coreceptor Impair gp120 Binding and Human Immunodeficiency Virus Type 1 Entry , 1998, Journal of Virology.

[34]  H. Klenk,et al.  Inhibition of furin-mediated cleavage activation of HIV-1 glycoprotein gpl60 , 1992, Nature.

[35]  D. Wong,et al.  Hepatitis C Virus Structural Proteins Assemble into Viruslike Particles in Insect Cells , 1998, Journal of Virology.

[36]  Martin Oppermann,et al.  Characterization of Sequence Determinants within the Carboxyl-terminal Domain of Chemokine Receptor CCR5 That Regulate Signaling and Receptor Internalization* , 2001, The Journal of Biological Chemistry.

[37]  R. Wagner,et al.  Increased incorporation of chimeric human immunodeficiency virus type 1 gp120 proteins into Pr55gag virus-like particles by an Epstein-Barr virus gp220/350-derived transmembrane domain. , 1997, Virology.

[38]  C. Malboeuf,et al.  Human papillomavirus-like particles mediate functional delivery of plasmid DNA to antigen presenting cells in vivo. , 2007, Vaccine.

[39]  R. Blumenthal,et al.  Conformational Changes in Cell Surface HIV-1 Envelope Glycoproteins Are Triggered by Cooperation between Cell Surface CD4 and Co-receptors* , 1998, The Journal of Biological Chemistry.

[40]  T. Matthews,et al.  Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[41]  M. Kozlov,et al.  Protein-lipid interplay in fusion and fission of biological membranes. , 2003, Annual review of biochemistry.

[42]  J. Schlessinger,et al.  Signal Transduction Due to HIV-1 Envelope Interactions with Chemokine Receptors CXCR4 or CCR5 , 1997, The Journal of experimental medicine.

[43]  J. Lachowicz,et al.  Piperazine-based CCR5 antagonists as HIV-1 inhibitors. IV. Discovery of 1-[(4,6-dimethyl-5-pyrimidinyl)carbonyl]- 4-[4-[2-methoxy-1(R)-4-(trifluoromethyl)phenyl]ethyl-3(S)-methyl-1-piperazinyl]- 4-methylpiperidine (Sch-417690/Sch-D), a potent, highly selective, and orally bioavailable CCR5 antagonis , 2004, Journal of medicinal chemistry.

[44]  John P. Moore,et al.  Stabilization of the Soluble, Cleaved, Trimeric Form of the Envelope Glycoprotein Complex of Human Immunodeficiency Virus Type 1 , 2002, Journal of Virology.

[45]  R. Redfield,et al.  Antiviral activity of single-dose PRO 140, a CCR5 monoclonal antibody, in HIV-infected adults. , 2008, The Journal of infectious diseases.

[46]  M. Yáñez-Mó,et al.  Involvement of phosphatidylinositol 3-kinase in stromal cell-derived factor-1 alpha-induced lymphocyte polarization and chemotaxis. , 1999, Journal of immunology.

[47]  M. Bachmann,et al.  Displaying Fel d1 on virus-like particles prevents reactogenicity despite greatly enhanced immunogenicity: a novel therapy for cat allergy , 2009, The Journal of experimental medicine.

[48]  R. Ganju,et al.  The α-Chemokine, Stromal Cell-derived Factor-1α, Binds to the Transmembrane G-protein-coupled CXCR-4 Receptor and Activates Multiple Signal Transduction Pathways* , 1998, The Journal of Biological Chemistry.

[49]  R. Doms,et al.  Use of GPR1, GPR15, and STRL33 as coreceptors by diverse human immunodeficiency virus type 1 and simian immunodeficiency virus envelope proteins. , 1998, Virology.

[50]  E. Rybicki,et al.  Chimaeric HIV-1 subtype C Gag molecules with large in-frame C-terminal polypeptide fusions form virus-like particles. , 2008, Virus research.

[51]  S. Shorte,et al.  CXCR4-Tropic HIV-1 Envelope Glycoprotein Functions as a Viral Chemokine in Unstimulated Primary CD4+ T Lymphocytes1 , 2004, Journal of Immunology.

[52]  K. Nagashima,et al.  Chimeric HIV-1 virus-like particles containing gp120 epitopes as a result of a ribosomal frameshift elicit Gag- and SU-specific murine cytotoxic T-lymphocyte activities. , 1997, Virology.

[53]  R. Doms,et al.  A seven-transmembrane domain receptor involved in fusion and entry of T-cell-tropic human immunodeficiency virus type 1 strains , 1996, Journal of virology.

[54]  M. Locati,et al.  HIV-1 coreceptor activity of CCR5 and its inhibition by chemokines: independence from G protein signaling and importance of coreceptor downmodulation. , 1997, Virology.

[55]  D. Peabody,et al.  Immunogenic display of diverse peptides on virus-like particles of RNA phage MS2. , 2008, Journal of molecular biology.

[56]  G. Simmons,et al.  Primary Human Immunodeficiency Virus Type 2 (HIV-2) Isolates Infect CD4-Negative Cells via CCR5 and CXCR4: Comparison with HIV-1 and Simian Immunodeficiency Virus and Relevance to Cell Tropism In Vivo , 1999, Journal of Virology.

[57]  C. Broder,et al.  Mutagenesis of CXCR4 Identifies Important Domains for Human Immunodeficiency Virus Type 1 X4 Isolate Envelope-Mediated Membrane Fusion and Virus Entry and Reveals Cryptic Coreceptor Activity for R5 Isolates , 1999, Journal of Virology.

[58]  W. Au,et al.  Human Immunodeficiency Virus Type 1 Uses Lipid Raft-Colocalized CD4 and Chemokine Receptors for Productive Entry into CD4+ T Cells , 2002, Journal of Virology.

[59]  J. Binley,et al.  A comparative immunogenicity study of HIV-1 virus-like particles bearing various forms of envelope proteins, particles bearing no envelope and soluble monomeric gp120. , 2007, Virology.

[60]  N. Heveker,et al.  Identification of Residues of CXCR4 Critical for Human Immunodeficiency Virus Coreceptor and Chemokine Receptor Activities* , 2000, The Journal of Biological Chemistry.

[61]  R. Wyatt,et al.  Tyrosine-sulfate isosteres of CCR5 N-terminus as tools for studying HIV-1 entry. , 2008, Bioorganic & medicinal chemistry.

[62]  I. Frazer,et al.  Chimeric human papilloma virus-simian/human immunodeficiency virus virus-like-particle vaccines: immunogenicity and protective efficacy in macaques. , 2002, Virology.

[63]  J. Park,et al.  Multiple-Dose Escalation Study of the Safety, Pharmacokinetics, and Biologic Activity of Oral AMD070, a Selective CXCR4 Receptor Inhibitor, in Human Subjects , 2007, Antimicrobial Agents and Chemotherapy.

[64]  M. Prevost,et al.  High efficient production of Pr55(gag) virus-like particles expressing multiple HIV-1 epitopes, including a gp120 protein derived from an Ugandan HIV-1 isolate of subtype A. , 2001, Antiviral research.

[65]  D. Ho,et al.  Genetically divergent strains of simian immunodeficiency virus use CCR5 as a coreceptor for entry , 1997, Journal of virology.

[66]  G. Song,et al.  Papillomavirus virus-like particles as vehicles for the delivery of epitopes or genes , 2006, Archives of Virology.

[67]  J. Sodroski,et al.  Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody , 1998, Nature.

[68]  J. Sodroski,et al.  The Level of CD4 Expression Limits Infection of Primary Rhesus Monkey Macrophages by a T-Tropic Simian Immunodeficiency Virus and Macrophagetropic Human Immunodeficiency Viruses , 2000, Journal of Virology.

[69]  A. Burny,et al.  The GAG precursor of simian immunodeficiency virus assembles into virus‐like particles. , 1989, EMBO Journal.

[70]  S. Harrison.  Mechanism of Membrane Fusion by Viral Envelope Proteins , 2005, Advances in Virus Research.

[71]  R. Doms,et al.  The entry of entry inhibitors: A fusion of science and medicine , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[72]  I. Weissman,et al.  Endoproteolytic cleavage of gp160 is required for the activation of human immunodeficiency virus , 1988, Cell.

[73]  M. Luftig,et al.  Structural basis for HIV-1 neutralization by a gp41 fusion intermediate–directed antibody , 2006, Nature Structural &Molecular Biology.

[74]  A. Kingsman,et al.  Hybrid human immunodeficiency virus Gag particles as an antigen carrier system: induction of cytotoxic T-cell and humoral responses by a Gag:V3 fusion , 1993, Journal of virology.

[75]  R. Means,et al.  Simian immunodeficiency virus variants with differential T-cell and macrophage tropism use CCR5 and an unidentified cofactor expressed in CEMx174 cells for efficient entry , 1997, Journal of virology.

[76]  Tiansen Li,et al.  DNA vaccine-encapsulated virus-like particles derived from an orally transmissible virus stimulate mucosal and systemic immune responses by oral administration , 2004, Gene Therapy.

[77]  A. Haase,et al.  Early Resolution of Acute Immune Activation and Induction of PD-1 in SIV-Infected Sooty Mangabeys Distinguishes Nonpathogenic from Pathogenic Infection in Rhesus Macaques12 , 2008, The Journal of Immunology.

[78]  R. Desrosiers,et al.  Use of Infectious Molecular Clones of Simian Immunodeficiency Virus for Pathogenesis Studies , 1989, Journal of medical primatology.

[79]  R. Desrosiers,et al.  Induction of AIDS-like disease in macaque monkeys with T-cell tropic retrovirus STLV-III. , 1985, Science.

[80]  F. Buonaguro,et al.  Virus-like particles as particulate vaccines. , 2010, Current HIV research.

[81]  E. Jacobs,et al.  Assembly and release of HIV-1 precursor Pr55 gag virus-like particles from recombinant baculovirus-infected insect cells , 1989, Cell.

[82]  P. Earl,et al.  Folding, interaction with GRP78-BiP, assembly, and transport of the human immunodeficiency virus type 1 envelope protein , 1991, Journal of virology.

[83]  R. Doms,et al.  Amino Acid 324 in the Simian Immunodeficiency Virus SIVmac V3 Loop Can Confer CD4 Independence and Modulate the Interaction with CCR5 and Alternative Coreceptors , 2004, Journal of Virology.

[84]  F. Buonaguro,et al.  DNA-VLP prime-boost intra-nasal immunization induces cellular and humoral anti-HIV-1 systemic and mucosal immunity with cross-clade neutralizing activity. , 2007, Vaccine.

[85]  Arvind H. Patel,et al.  Interaction of Hepatitis C Virus-Like Particles and Cells: a Model System for Studying Viral Binding and Entry , 2002, Journal of Virology.

[86]  Tongqing Zhou,et al.  Structure-Based Stabilization of HIV-1 gp120 Enhances Humoral Immune Responses to the Induced Co-Receptor Binding Site , 2009, PLoS pathogens.

[87]  F. Barré-Sinoussi,et al.  Nonpathogenic SIV infection of African green monkeys induces a strong but rapidly controlled type I IFN response. , 2009, The Journal of clinical investigation.

[88]  Anthony Wood,et al.  The discovery of the CCR5 receptor antagonist, UK-427,857, a new agent for the treatment of HIV infection and AIDS. , 2005, Progress in medicinal chemistry.

[89]  D. Lowy,et al.  Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[90]  J. Benovic,et al.  Regulation of CXCR4 signaling. , 2007, Biochimica et biophysica acta.

[91]  P S Kim,et al.  Mechanisms of viral membrane fusion and its inhibition. , 2001, Annual review of biochemistry.

[92]  N. Heveker,et al.  Effect of Mutations in the Second Extracellular Loop of CXCR4 on Its Utilization by Human and Feline Immunodeficiency Viruses , 1999, Journal of Virology.

[93]  D. Kabat,et al.  Cooperation of Multiple CCR5 Coreceptors Is Required for Infections by Human Immunodeficiency Virus Type 1 , 2000, Journal of Virology.

[94]  F. Sánchez‐Madrid,et al.  A Role for the Rho-p160 Rho Coiled-Coil Kinase Axis in the Chemokine Stromal Cell-Derived Factor-1α-Induced Lymphocyte Actomyosin and Microtubular Organization and Chemotaxis1 , 2002, The Journal of Immunology.

[95]  R. Wyatt,et al.  Selective recognition of oligomeric HIV-1 primary isolate envelope glycoproteins by potently neutralizing ligands requires efficient precursor cleavage. , 2005, Virology.

[96]  M. Schreiber,et al.  Infection of cells expressing CXCR4 mutants lacking N-glycosylation at the N-terminal extracellular domain is enhanced for R5X4-dualtropic human immunodeficiency virus type-1 , 2002, BMC infectious diseases.

[97]  R. Doms,et al.  Palmitoylation of CCR5 Is Critical for Receptor Trafficking and Efficient Activation of Intracellular Signaling Pathways* , 2001, The Journal of Biological Chemistry.

[98]  P S Kim,et al.  Crystal structure of the simian immunodeficiency virus (SIV) gp41 core: conserved helical interactions underlie the broad inhibitory activity of gp41 peptides. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[99]  Q. Sattentau,et al.  Analysis of Memory B Cell Responses and Isolation of Novel Monoclonal Antibodies with Neutralizing Breadth from HIV-1-Infected Individuals , 2010, PloS one.

[100]  D. Thompson,et al.  Entry of R5X4 and X4 human immunodeficiency virus type 1 strains is mediated by negatively charged and tyrosine residues in the amino-terminal domain and the second extracellular loop of CXCR4. , 2000, Virology.

[101]  C. Broder,et al.  Marked structural and functional heterogeneity in CXCR4: Separation of HIV‐1 and SDF‐1α responses , 2005, Immunology and cell biology.

[102]  P. Pumpens,et al.  Recombinant RNA phage Q beta capsid particles synthesized and self-assembled in Escherichia coli. , 1993, Gene.

[103]  J. Sodroski,et al.  Solid-Phase Proteoliposomes Containing Human Immunodeficiency Virus Envelope Glycoproteins , 2002, Journal of Virology.

[104]  R. Bonavia,et al.  Stromal cell-derived factor-1alpha (SDF-1alpha/CXCL12) stimulates ovarian cancer cell growth through the EGF receptor transactivation. , 2005, Experimental cell research.

[105]  J. Sodroski,et al.  CD4-Induced Conformational Changes in the Human Immunodeficiency Virus Type 1 gp120 Glycoprotein: Consequences for Virus Entry and Neutralization , 1998, Journal of Virology.

[106]  G. Hummer,et al.  Differential inhibition of HIV-1 and SIV envelope-mediated cell fusion by C34 peptides derived from the C-terminal heptad repeat of gp41 from diverse strains of HIV-1, HIV-2, and SIV. , 2005, Journal of medicinal chemistry.

[107]  P. Roy,et al.  Synthesis of bluetongue virus (BTV) corelike particles by a recombinant baculovirus expressing the two major structural core proteins of BTV , 1990, Journal of virology.

[108]  M. Hilleman,et al.  Human hepatitis B vaccine from recombinant yeast , 1984, Nature.

[109]  J. Sodroski,et al.  The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. , 1998, Science.

[110]  J. Oxford,et al.  An experimental chemically inactivated HIV-1 vaccine induces antibodies that neutralize homologous and heterologous viruses. , 1995, Vaccine.

[111]  R. Doms,et al.  Determinants of CD4 Independence for a Human Immunodeficiency Virus Type 1 Variant Map outside Regions Required for Coreceptor Specificity , 1999, Journal of Virology.

[112]  Rino Rappuoli,et al.  Structure-based antigen design: a strategy for next generation vaccines , 2008, Trends in Biotechnology.

[113]  K. Peden,et al.  HIV coreceptors: role of structure, posttranslational modifications, and internalization in viral-cell fusion and as targets for entry inhibitors. , 2003, Biochimica et biophysica acta.

[114]  N Vasilieva,et al.  A Tyrosine-sulfated Peptide Based on the N Terminus of CCR5 Interacts with a CD4-enhanced Epitope of the HIV-1 gp120 Envelope Glycoprotein and Inhibits HIV-1 Entry* , 2000, The Journal of Biological Chemistry.

[115]  G. Melikyan,et al.  Evidence That the Transition of HIV-1 Gp41 into a Six-Helix Bundle, Not the Bundle Configuration, Induces Membrane Fusion , 2000, The Journal of cell biology.

[116]  D. Weissman,et al.  Macrophage-tropic HIV and SIV envelope proteins induce a signal through the CCR5 chemokine receptor , 1997, Nature.

[117]  R. Doms,et al.  Determinants within gp120 and gp41 contribute to CD4 independence of SIV Envs. , 2004, Virology.

[118]  V. Georgiev.  Virology , 1955, Nature.

[119]  L. Stamatatos,et al.  Changes in the Immunogenic Properties of Soluble gp140 Human Immunodeficiency Virus Envelope Constructs upon Partial Deletion of the Second Hypervariable Region , 2003, Journal of Virology.

[120]  Dominique Schols,et al.  Inhibition of Human Immunodeficiency Virus Replication by a Dual CCR5/CXCR4 Antagonist , 2004, Journal of Virology.

[121]  David A. Price,et al.  Maraviroc (UK-427,857), a Potent, Orally Bioavailable, and Selective Small-Molecule Inhibitor of Chemokine Receptor CCR5 with Broad-Spectrum Anti-Human Immunodeficiency Virus Type 1 Activity , 2005, Antimicrobial Agents and Chemotherapy.

[122]  C. Broder,et al.  N-Linked Glycosylation of CXCR4 Masks Coreceptor Function for CCR5-Dependent Human Immunodeficiency Virus Type 1 Isolates , 2000, Journal of Virology.

[123]  M. Stone,et al.  Regulation of chemokine recognition by site-specific tyrosine sulfation of receptor peptides. , 2009, Chemistry & biology.

[124]  J. Binley,et al.  Nature of Nonfunctional Envelope Proteins on the Surface of Human Immunodeficiency Virus Type 1 , 2006, Journal of Virology.

[125]  D. Weissman,et al.  A Membrane-proximal Basic Domain and Cysteine Cluster in the C-terminal Tail of CCR5 Constitute a Bipartite Motif Critical for Cell Surface Expression* , 2001, The Journal of Biological Chemistry.

[126]  J. Binley,et al.  A Recombinant Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Complex Stabilized by an Intermolecular Disulfide Bond between the gp120 and gp41 Subunits Is an Antigenic Mimic of the Trimeric Virion-Associated Structure , 2000, Journal of Virology.

[127]  G P Overbeek,et al.  Nucleotide sequence of a ssRNA phage from Acinetobacter: kinship to coliphages. , 2002, The Journal of general virology.

[128]  J. Sodroski,et al.  Modifications That Stabilize Human Immunodeficiency Virus Envelope Glycoprotein Trimers in Solution , 2000, Journal of virology.

[129]  G. Silvestri.  Naturally SIV‐infected sooty mangabeys: are we closer to understanding why they do not develop AIDS? , 2005, Journal of medical primatology.

[130]  F. Buonaguro,et al.  Baculovirus-Derived Human Immunodeficiency Virus Type 1 Virus-Like Particles Activate Dendritic Cells and Induce Ex Vivo T-Cell Responses , 2006, Journal of Virology.

[131]  S. Harrison,et al.  Atomic structure of the ectodomain from HIV-1 gp41 , 1997, Nature.

[132]  C. Weiss,et al.  Capture of an early fusion-active conformation of HIV-1 gp41 , 1998, Nature Structural Biology.

[133]  J. M. Seguí-Simarro,et al.  Human papillomavirus L1 protein expressed in tobacco chloroplasts self-assembles into virus-like particles that are highly immunogenic. , 2008, Plant biotechnology journal.

[134]  R. Bonavia,et al.  Stromal Cell-derived Factor 1α Stimulates Human Glioblastoma Cell Growth through the Activation of Both Extracellular Signal-regulated Kinases 1/2 and Akt , 2003 .

[135]  R. Desrosiers,et al.  Mechanisms for Adaptation of Simian Immunodeficiency Virus to Replication in Alveolar Macrophages , 2000, Journal of Virology.

[136]  J. Sodroski,et al.  Sialylated O-Glycans and Sulfated Tyrosines in the NH2-Terminal Domain of CC Chemokine Receptor 5 Contribute to High Affinity Binding of Chemokines , 2001, The Journal of experimental medicine.

[137]  M. Lederman,et al.  Safety, pharmacokinetics, and antiviral activity of HGS004, a novel fully human IgG4 monoclonal antibody against CCR5, in HIV-1-infected patients. , 2008, The Journal of infectious diseases.

[138]  L. Dong,et al.  HIV Envelope-CXCR4 Signaling Activates Cofilin to Overcome Cortical Actin Restriction in Resting CD4 T Cells , 2008, Cell.

[139]  S. Zolla-Pazner,et al.  Dissection of Human Immunodeficiency Virus Type 1 Entry with Neutralizing Antibodies to gp41 Fusion Intermediates , 2002, Journal of Virology.

[140]  R. Doms,et al.  Unique Pattern of Convergent Envelope Evolution in Simian Immunodeficiency Virus-Infected Rapid Progressor Macaques: Association with CD4-Independent Usage of CCR5 , 2003, Journal of Virology.

[141]  J. Westwick,et al.  The CXC chemokine stromal cell-derived factor activates a Gi-coupled phosphoinositide 3-kinase in T lymphocytes. , 1999, Journal of immunology.

[142]  Q. Sattentau,et al.  Conformational changes induced in the human immunodeficiency virus envelope glycoprotein by soluble CD4 binding , 1991, The Journal of experimental medicine.

[143]  J. Sodroski,et al.  N-linked glycosylation in the CXCR4 N-terminus inhibits binding to HIV-1 envelope glycoproteins. , 2004, Virology.

[144]  Y. Percherancier,et al.  Palmitoylation-dependent Control of Degradation, Life Span, and Membrane Expression of the CCR5 Receptor* , 2001, The Journal of Biological Chemistry.

[145]  E. Snezhkov,et al.  Formation of poliovirus-like particles by recombinant baculoviruses expressing the individual VP0, VP3, and VP1 proteins by comparison to particles derived from the expressed poliovirus polyprotein. , 1993, Virology.

[146]  S. Harrison,et al.  A Chimeric Protein of Simian Immunodeficiency Virus Envelope Glycoprotein gp140 and Escherichia coli Aspartate Transcarbamoylase , 2004, Journal of Virology.

[147]  R. Compans,et al.  Influenza vaccines based on virus-like particles. , 2009, Virus research.

[148]  William C. Olson,et al.  Evaluating the Immunogenicity of a Disulfide-Stabilized, Cleaved, Trimeric Form of the Envelope Glycoprotein Complex of Human Immunodeficiency Virus Type 1 , 2005, Journal of Virology.

[149]  J. Hoxie,et al.  Inhibition of human immunodeficiency virus fusion by a monoclonal antibody to a coreceptor (CXCR4) is both cell type and virus strain dependent , 1997, Journal of virology.

[150]  T L Hoffman,et al.  Stable exposure of the coreceptor-binding site in a CD4-independent HIV-1 envelope protein. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[151]  J. Sodroski,et al.  Highly Stable Trimers Formed by Human Immunodeficiency Virus Type 1 Envelope Glycoproteins Fused with the Trimeric Motif of T4 Bacteriophage Fibritin , 2002, Journal of Virology.

[152]  D. Weiner,et al.  Monkeying around with HIV vaccines: using rhesus macaques to define 'gatekeepers' for clinical trials , 2009, Nature Reviews Immunology.

[153]  Min Lu,et al.  Oligomeric and Conformational Properties of a Proteolytically Mature, Disulfide-Stabilized Human Immunodeficiency Virus Type 1 gp140 Envelope Glycoprotein , 2002, Journal of Virology.

[154]  J. Sodroski,et al.  Characterization of Stable, Soluble Trimers Containing Complete Ectodomains of Human Immunodeficiency Virus Type 1 Envelope Glycoproteins , 2000, Journal of Virology.

[155]  F. Buonaguro,et al.  Induction of Systemic and Mucosal Cross-Clade Neutralizing Antibodies in BALB/c Mice Immunized with Human Immunodeficiency Virus Type 1 Clade A Virus-Like Particles Administered by Different Routes of Inoculation , 2005, Journal of Virology.

[156]  H. Katinger,et al.  Exposure of the membrane-proximal external region of HIV-1 gp41 in the course of HIV-1 envelope glycoprotein-mediated fusion. , 2007, Biochemistry.

[157]  T. Hope,et al.  Mobility of the Human Immunodeficiency Virus (HIV) Receptor CD4 and Coreceptor CCR5 in Living Cells: Implications for HIV Fusion and Entry Events , 2004, Journal of Virology.

[158]  M. Klotman,et al.  Phosphatidylinositol 3-Kinase Regulates Human Immunodeficiency Virus Type 1 Replication following Viral Entry in Primary CD4+ T Lymphocytes and Macrophages , 2003, Journal of Virology.

[159]  K. Matsubara,et al.  Expression of hepatitis B virus core antigen gene in Saccharomyces cerevisiae: synthesis of two polypeptides translated from different initiation codons , 1986, Journal of virology.

[160]  S W Lin,et al.  Specific interaction of CCR5 amino-terminal domain peptides containing sulfotyrosines with HIV-1 envelope glycoprotein gp120. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[161]  L. Racioppi,et al.  Induction of neutralizing antibodies and cytotoxic T lymphocytes in Balb/c mice immunized with virus-like particles presenting a gp120 molecule from a HIV-1 isolate of clade A. , 2002, Antiviral research.